Group 1 - The board of directors of Shanghai Changlian International Logistics Co., Ltd. held its 12th meeting of the 4th session on August 27, 2025, with all 11 directors present, ensuring compliance with legal and procedural requirements [1][2] - The board unanimously approved the establishment of Shanghai Changlian Baifu Pharmaceutical Co., Ltd. in partnership with Shanghai Waigaoqiao Biopharmaceutical Industry Development Co., Ltd., with the company holding a 60% stake [2]

Core Viewpoint - Changlian Co., Ltd. (603648.SH) reported a decline in revenue and net profit for the first half of 2025, indicating challenges in its operational performance compared to peers in the industry [1][3]. Financial Performance - The company's total revenue for the first half of 2025 was 739 million yuan, ranking 27th among disclosed peers, a decrease of 89.35 million yuan or 10.78% year-on-year [1]. - The net profit attributable to shareholders was 68.31 million yuan, ranking 19th among peers, down by 11.70 million yuan or 14.62% year-on-year [1]. - Operating cash flow was 100 million yuan, ranking 18th among peers, a decrease of 37.56 million yuan or 27.24% year-on-year [1]. Key Ratios - The latest debt-to-asset ratio was 26.94%, ranking 4th among peers, an increase of 4.98 percentage points from the previous quarter and 7.70 percentage points from the same period last year [3]. - The gross profit margin was 20.51%, ranking 8th among peers, an increase of 0.25 percentage points from the previous quarter and 0.49 percentage points year-on-year [3]. - Return on equity (ROE) was 3.78%, ranking 15th among peers, a decrease of 0.38 percentage points year-on-year [3]. Earnings Per Share and Turnover - The diluted earnings per share were 0.19 yuan, ranking 18th among peers, a decrease of 0.03 yuan or 13.95% year-on-year [3]. - The total asset turnover ratio was 0.29 times, ranking 29th among peers, a decrease of 0.05 times year-on-year [3]. - The inventory turnover ratio was 31.06 times, ranking 16th among peers, an increase of 19.11 times or 159.80% year-on-year [3]. Shareholder Structure - The number of shareholders was 21,400, with the top ten shareholders holding 211 million shares, accounting for 58.32% of the total share capital [3]. - The largest shareholder is the State-owned Assets Supervision and Administration Commission of Pudong New Area, holding 25.30% [3].

Core Viewpoint - Shanghai Changlian International Logistics Co., Ltd. plans to establish a joint venture, Shanghai Changlian Baifu Pharmaceutical Co., Ltd., with Shanghai Waigaoqiao Biomedical Industry Development Co., Ltd. The registered capital of the new company will be RMB 50 million, with Changlian contributing RMB 30 million for a 60% stake, while the biomedical company will contribute RMB 20 million for a 40% stake. This project is not expected to have a significant short-term impact on the company's revenue, profit, or cash flow [3][4][5]. Company Overview - The new company, Shanghai Changlian Baifu Pharmaceutical Co., Ltd., will focus on supply chain management services in the pharmaceutical sector, leveraging Changlian's existing advantages in the medical device sector [5][6]. - The establishment of the new company aligns with the company's strategic goal of expanding into the pharmaceutical sector, enhancing its overall competitiveness [11]. Investment and Transaction Details - The joint investment constitutes a related party transaction, with the investment amount of RMB 30 million representing 1.62% of the company's net assets as of 2024 [6][9]. - The transaction has been approved by the company's independent directors, audit committee, board of directors, and supervisory board, and does not require shareholder approval [4][15][30]. Business Synergy and Market Context - The new company aims to create a standardized logistics warehouse for pharmaceuticals, supporting the development of the biomedical industry in the Shanghai Free Trade Zone [5][10]. - The establishment of the new company is expected to enhance the regional investment ecosystem and foster the development of pharmaceutical research and manufacturing projects [5][9]. Governance Structure - The new company will have a governance structure consisting of a shareholders' meeting, a board of directors, and a general manager, with the board comprising five members [11][12].

Group 1 - The company announced that its fourth board meeting approved multiple proposals, including the review of the general manager's work report for the first half of 2025 [2]

Group 1 - The company Changlian Co., Ltd. announced on the evening of August 28 that its fourth supervisory board's tenth meeting approved the proposal regarding the company's semi-annual report for the first half of 2025 and its summary [2]

Group 1 - The company reported a revenue of 739 million yuan for the first half of 2025, representing a year-on-year decrease of 10.78% [1] - The net profit attributable to shareholders was 68.31 million yuan, down 14.62% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 56.47 million yuan, a decline of 21.57% compared to the previous year [1] - The basic earnings per share stood at 0.1885 yuan [1]

证券代码：603648 证券简称：畅联股份 公告编号：2025-022 上海畅联国际物流股份有限公司 第四届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2、审议通过了《关于审议公司对外投资暨关联交易项目的议案》 表决结果：4 票赞成、0 票反对、0 票弃权，监事会主席李健飞先生回避表决。 一、监事会会议召开情况 上海畅联国际物流股份有限公司（以下简称"公司"）第四届监事会第十次 会议于 2025 年 8 月 27 日在公司会议室以现场表决的方式召开。会议通知及会议 材料于 2025 年 8 月 11 日以电子邮件、电话等形式发出。本次会议由监事会主席 李健飞先生主持，应出席监事 5 名，实际出席监事 5 名。会议参与表决人数及召 集、召开程序符合《公司法》和《公司章程》的有关规定，所作决议合法有效。 本次监事会会议审议并通过了以下议案： 1、审议通过了《关于审议公司 2025 年半年度报告及其摘要的议案》 公司 2025 年半年度报告的编制和审议程序符合法律、法规、《公司章程》和 公司内部管理制度 ...

上海畅联国际物流股份有限公司（以下简称"公司"）第四届董事会第十二 次会议于 2025 年 8 月 27 日在公司会议室以现场结合通讯表决方式召开。会议通 知及会议材料于 2025 年 8 月 11 日以电子邮件、电话等形式发出。本次会议由董 事长尹强先生主持，应出席董事 11 名，实际出席董事 11 名，其中亲自出席会议 的董事 10 名，副董事长俞勇先生因个人原因委托董事长尹强先生代为出席。会议 参与表决人数及召集、召开程序符合《公司法》和《公司章程》的有关规定，所 作决议合法有效。 二、董事会会议审议情况 证券代码：603648 证券简称：畅联股份 公告编号：2025-021 上海畅联国际物流股份有限公司 第四届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 本次董事会会议审议并通过了以下议案： 1、审议通过了《关于审议总经理 2025 上半年度工作报告的议案》 表决结果：11 票赞成、0 票反对、0 票弃权，0 票回避表决。 2、审议通过了《关于审议公司 2025 年 ...

格隆汇8月28日丨畅联股份(603648.SH)公布半年度报告，营业收入7.39亿元，同比下降10.78%，归属于 上市公司股东的净利润6830.97万元，同比下降14.62%，归属于上市公司股东的扣除非经常性损益的净 利润5646.5万元，同比下降21.57%。 ...

上海畅联国际物流股份有限公司2025 年半年度报告 公司代码：603648 公司简称：畅联股份 上海畅联国际物流股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 未出席董事情况 | 未出席董事职务 | 未出席董事姓名 | 未出席董事的原因说明 | 被委托人姓名 | | --- | --- | --- | --- | | 董事 | 俞勇 | 个人原因 | 尹强 | 三、 本半年度报告未经审计。 四、 公司负责人徐峰、主管会计工作负责人种永及会计机构负责人（会计主管人员）杜丽芳声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 上海畅联国际物流股份有限公司 2025 年半年度报告 1 / 175 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告如涉及未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺，敬请投 资者注意投资风险。 七、 是否存在被控股股东及其他关联方非 ...